---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-307541"
form_type: "8-K"
ticker: "BIOA"
cik: "0001709941"
company_name: "BioAge Labs, Inc."
filed_at: "2025-12-04T23:59:59+00:00"
generated_at: "2026-05-16T14:49:57.188646+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BioAge reports positive Phase 1 interim data for NLRP3 inhibitor BGE-102; 90-98% IL-1β suppression

## Summary
- BGE-102 well-tolerated across all doses (SAD: 10-120 mg; MAD: 60-120 mg); AEs mild/moderate, all resolved.
- 90-98% suppression of IL-1β at Day 14; doses ≥60 mg exceeded IC90 in CSF, demonstrating high brain penetration.
- Phase 1 expanded to MAD cohorts in obese participants with elevated hsCRP; data expected 1H26.
- Phase 2a proof-of-concept planned for 1H26 (100 patients, 12 weeks, primary endpoint % hsCRP change); data readout 2H26.
- Pharmacokinetics support once-daily oral dosing; dose proportionality observed.

## SEC filing metadata
- accession: 0001193125-25-307541
- form_type: 8-K
- ticker: BIOA
- cik: 0001709941
- company_name: BioAge Labs, Inc.
- filed_at: 2025-12-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1709941/000119312525307541/0001193125-25-307541-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1709941/000119312525307541/bioa-20251204.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-307541
- JSON: https://secwatch.observer/filing/0001193125-25-307541.json
- Plain text: https://secwatch.observer/filing/0001193125-25-307541.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.